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NATIONAL
and Infectious Diseases (NIAID), the Division of AIDS
(DAIDS), the US Food and Drug Administration (FDAl. the
Office of Human Research and Protection (OHRP), the US
Waiter Reid Army Institute for Research, vaccine
developers, biotechnology companies, the pharmaceutical
industry, universities and research institutions.
SMVI is a broad-based community research entity which
co-ordinates vaccine research and development work at
The South African AIDS Vaccine Initiative [SMVI) was
formed by Cabinet in 1999 to co-ordinate the research,
development and testing of HIV vaccines in South Africa.
SMVI is based at the South African Medical Research
Council (MRC) and is an integral player in the international
networks. It is funded by the South African Government
and Eskom, and also by the NIH, the European Union and
other international organisations.
The HVTN co-ordinates its activities through a number of
committees and task teams including a scientific steering
committee, scientific committees covering the various
phases of clinical trials (phases I, 11 and 111) and laboratory
sciences. Working groups or teams address development,
protocols, primary infections, paediatrics and adolescents,
and non-human primates.
This operation is co-ordinated by various mechanisms such
as biannual HVTN full group meetings, conference calls, etc.
in a standardised manner guided by the HVTN's Manual of
Operations [MOP}.
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This article describes the infrastructure in global, national
and site or regional levels. It concentrates mainly on the
HVTN network at an international level and on SMVI at a
national level. Information on IAVI can be accessed via the
Internet address given above.
GLOBAL
Current interventions have failed to sustain control in the
spread of the HIV epidemic. A preventive HIV vaccine is
considered the best hope of curbing the epidemic, and
considerable international and national resources are being
directed to this end. This has resulted in an alignment of
these resources into two main coherent international
networks, namely the HIV Vaccine Trials Network (HVTN -
www.hvtn.org) and the International AIDS Vaccine
Initiative (IAVI - www.iavi.org). Their core aim is to
accelerate the production of a safe, effective and
affordable preventive HIV vaccine. The South African AIDS
Vaccine Initiative [SMVI - www.saavi.org) is a vital
contributor to and partner in both these collaborations.
History has shown that vaccines have provided the key to
epidemic disease control. It is imperative, however, that
vaccination is integrated into effective public health
programmes. These include life skills education, sanitation,
potable water supply, environmental and other health care
and service provision.
BACKGROUND
The infrastructure developed in this quest so far is both
impressive and complex. It is structured to harness the
considerable intellectual input and investments required to
achieve the goal of an effective HIV vaccine in the shortest
possible time.
THE INFRASTRUCTURE SUPPORTING HIV
VACCINE CLINICAL TRIALS
The HVTN is based in Seattle in Washington, USA. Its
operations comprise a core operations centre, a statistical
and data management centre, central laboratories, a
community advisory board co-ordinating directorate, and
HIV vaccine clinical trial units. Unkages have been
established at various levels including the National
Institutes of Health (NIH), the National Institute of Allergy
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various South African academic institutes such as
• the National Institute of Communicable Diseases
(NICD), which will examine and track the immune
responses to HIV/AIDS test vaccines
• research teams based at the universities of Cape Town
and Stellenbosch that are aiming to develop new test
vaccines and track the prevalence of circulating HIV
strains
• an HIV/AIDS Vaccines Ethics Group (HAVEG) at the
University of Natal
• the South African HIV Vaccine Action Campaign (SA
HIVAC), which is a consortium focusing on community
education, legal and human rights, as well as media and
communications
• a behavioural sciences group
• a primate research centre, and
• established clinical trial sites at the Perinatal HIV
Research Unit at Chris Hani-Baragwanath Hospital in
Soweto and at the MRC in Durban, as well as two
additional sites to be developed in Cape Town and
Orkney.
REGIONAL CUNICAl TRIAL UNITS
This vast infrastructure is geared to enable the clinical trial
sites to timeously enrol volunteer participants and
undertake clinical trials of suitable candidate HIV vaccines.
These units are geared to generate data of high quality to
answer the necessary research questions in the quest for a
safe, affordable and effective vaccine.
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These sites have many similarities with other clinical
research facilities. They require staffing, facilities and
equipment necessary to meet the exacting internationally
accepted requirements demanded of HIV vaccine research,
the ethical care and management of volunteer participants,
and meaningful community integration in all these
processes.
STAFF
The staff complement at these sites consists of the
principal investigator (PI), co-investigators, research
clinicians, pharmacists, laboratory technicians, nurses, data
managers, administrators, HIV/AIDS counsellors, social
scientists. community outreach personnel such as
educators. liaison officers and recruiters. and quality
assurance personnel. These units are usually supported by
information technology, financial, security and cleaning
staff. The staffing operation must be aligned to real
capacity building with the aim of meeting employment
equity legislative requirements.
All personnel need to have training, or be trained and
continually updated in the various aspects of clinical
research such as good clinical practice (GCP), the numerous
(50+) standard operating procedures (SOPs), MOPs and
protocol-specific requirements. Ongoing training aims to
enable them to meet their varied responsibilities within the
highly complex, sensitive arena of HIV clinical research. In
addition, frontline staff require media training to ensure
that a coherent, clear and co-ordinated message necessary
for such an undertaking is communicated to the public.
•
The Pis are responsible for the quality and integrity of the
conduct of vaccine clinical trials, the medical care of
participants to the highest ethical standards, protocol
conduct with the agreed approvals by the Medicines
Control Council (MCC) and the various ethics committees,
and also the provision of quality staffing, facilities and
equipment.
The PI's responsibilities to this end encompass submission
of protocol and amendments to the regulatory authorities
and adherence to the requirements of these regulatory
authorities with confidential data management and
transmission, and document storage. They are also
responsible for the education, recruitment, enrolment and
retention of participants, which encompasses a functional
community advisory board (CAB) and other community
mobilisation and education activities. Units also typi.cally
establish in-house voluntary counselling and testing {VCn
services which add to the recruitment process. The Pis
ensure compliance with the International Committee of
Harmonisation (ICH) GCP guidelines for the medical
management and monitoring of participants, vaccine
management such as cold-chain maintenance, storage,
reconstitution and administration, and specimen collection
in adherence to protocol, and sponsor policy and
procedures. They must also ensure that specimen
collection processing and shipment meets the
requirements of the International Air Transport Association
(lATA).
The PI is also responsible for the establishment, facilitation
and maintenance of CABs, which are required to reduce the
perceived power imbalance between researchers,
participants and communities. These CABs comprise
community representatives, and usually include
representation from community-based organisations
(CBOs), non-governmental organisations (NGOs),
traditional leaders and practitioners, faith-based
organisations, trade unions and governmental
departments, among others. CABs require training to
enable them to input meaningfully to the clinical trial
process such as the informed consent process,
inclusion/exclusion criteria, participant care, and
recruitment and retention issues.
These CABs are organised and co-ordinated internationally
in a highly structured way and exert a powerful infiuence
in ensuring appropriate, expedited HIV vaccine research.
FACIUTIES AND EQUIPMENT
Vaccine trial sites typically comprise examination rooms
supported by an emergency care facility, pharmacy and
laboratory, waiting and counselling areas, offices, secure
document storage rooms and freezer repositories.
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Standard equipment includes IT equipment and
networking, telephones and fax, photocopiers, scanners,
etc., as in most clinical trial units. In addition a pharmacy
equipped with fume extraction cupboards for safe vaccine
reconstitution, and -40°C freezers with temperature
controls, alarms, and logs to ensure continual temperature
controls is also required. An electrical back-up generator is
required to ensure uninterrupted power to run the freezers.
This is linked to a service company to ensure 24-hour
functionality.
The site laboratories are equipped and staffed mainly for
specimen preparation such as serum separation, peripheral
blood mononuclear cell (PBMC) isolation, specimen
shipment and tracking, test result management, and on-
site rapid testing such as pregnancy and HIV tests.
UNKAGES
Clinical trial units, apart from their links with international
and national HIV vaccine groups, communicate with many
organisations, institutions and people within the region in
which they operate. These include the government
Departments of Health at central, provincial and local
spheres, ethics committees, hospitals (both private and
state), clinics and GPs, CBOs, NGOs, faith-based
organisations, the media and trade unions.
CONCLUSION
This is an overview rather than an exhaustive description of
the fine detail which, of necessity, exists right down to the
needle tip or device delivering the HIV vaccine. These
minutiae, however, are all essential to ensure that the
correctly modified HIV antigenic fragments are delivered
safely and expeditiously into volunteer participants and
that all outcomes are managed appropriately.
Never before has a global endeavour of this magnitude and
intricacy been mounted in the search for a vaccine. The
development of the polio and smallpox vaccines was not
supported by a mustering of this intensity. We should
remind ourselves of the time it took to control smallpox -
from Or Jenner's inoculation of Master James Phipps in the
1760s to its eventual eradication in the 1970s - not
forgetting the vaccination activities predating this. By
contrast, some modern vaccines have been developed in
only a few decades.
Is this complicated infrastructure sufficient in terms of
quality, magnitude, courage and will to produce a safe,
effective and affordable preventive HIV vaccine within the
next decade) We hope so - but until such time, the public
health education, care and treatment programmes must
rise to meet the need.
MAY 2003
